Inozyme Pharma receives US$70 million in strategic investment

Inozyme Pharma is a developer of bone mineralization drugs, developing novel enzyme replacement therapy for bone mineralization disorders. Inozyme Pharma (INZY) announced that it has entered into a debt financing agreement of up to $70 million with K2 HealthVentures.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment